Target intelligence / Profile preview

Lipid A phosphate groups (LPS-P)

Target
LPS-P
Molecular classification
Bacterial cell wall component, Glycolipid component, Anionic surface group
01

Overview

Lipid A phosphate groups are the anionic moieties located at the 1 and 4' positions of the glucosamine disaccharide backbone of lipid A, which serves as the hydrophobic anchor of lipopolysaccharides (LPS) in Gram-negative bacteria (Raetz & Whitfield, 2002, Annu Rev Biochem). These phosphate groups are essential for maintaining the structural integrity of the bacterial outer membrane by forming ionic bridges with divalent cations like magnesium and calcium. In clinical medicine, these groups serve as the primary binding site for cationic polypeptide antibiotics, such as polymyxin B and colistin, which disrupt the membrane through electrostatic displacement of these cations (Velkov et al., 2010, J Med Chem). Beyond their structural role, the phosphate groups are critical for the recognition of LPS by the human TLR4/MD-2 receptor complex, which initiates the pro-inflammatory signaling cascade responsible for sepsis and septic shock (Park et al., 2009, Nature). Bacterial resistance often involves the enzymatic modification of these phosphate groups with moieties like phosphoethanolamine or 4-amino-4-deoxy-L-arabinose to reduce the overall negative charge and evade antibiotic binding (Liu et al., 2016, Lancet Infect Dis).

Other names
Lipopolysaccharide phosphate groupsLipid A 1-phosphateLipid A 4'-phosphateEndotoxin phosphate groupsLPS phosphate groups
02

Mechanism of action

Cationic drugs bind electrostatically to the negatively charged phosphate groups on lipid A, displacing divalent cations (Ca2+ and Mg2+) that stabilize the outer membrane, leading to membrane disruption and cell lysis (Velkov et al., 2013, Future Med Chem).

03

Biological functions

Outer membrane stabilizationEndotoxic activityCation bindingImmune response activation
04

Disease associations

Gram-negative bacterial infectionSepsisSeptic shockInflammation
05

Safety considerations

NephrotoxicityNeurotoxicityBacterial resistance via phosphate modification (e.g., mcr-1 gene mediated phosphoethanolamine addition)Narrow therapeutic index
06

Interacting drugs

Polymyxin B

4 more in the full profile.

07

Biomarkers

Lipopolysaccharide (LPS) levelsLPS-binding protein (LBP)Endotoxin activity assay (EAA)Procalcitonin

Beyond the preview

Go deeper on Lipid A phosphate groups (LPS-P).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lipid A phosphate groups (LPS-P).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call